Why Inari Medical (NARI) Stock Is Surging Tuesday - Inari Medical (NASDAQ:NARI)

Inari Medical Inc NARI reported preliminary Q4 FY22 sales of $107-$108.0 million, up 12% sequentially and 29% year-over-year (at the midpoint of the range), above the consensus of $99.12 million.
For FY22, the company reported preliminary revenue of $382.7-$383.7 million, up approximately 38% Y/Y, beating the consensus of $374.77 million.
Inari ended 2022 with over 275 U.S. sales territories.
"Our fourth quarter was successful and highly productive. We executed crisply across all five of our growth drivers and generated robust revenue growth," said Drew Hykes, CEO of Inari Medical.
Inari provided financial guidance for FY23 revenue of $470 million to $480 million, reflecting growth of approximately 23% to 25% over 2022, well above the consensus of $450.75 million.
Price Action: NARI shares are up 6.77% at $68.33 on the last check Tuesday.

Inari Medical Shares Jump On Better Than Expected Interim Sales For FY22